J Korean Soc Neonatol.  2005 May;12(1):32-41.

Effects of Maeil Human Milk Fortifier on Growth and Bone Mineralization in Preterm Infants

Affiliations
  • 1Department of Pediatrics Ajou University School of Medicine, Suwon, Korea. drparkms@ajou.ac.kr
  • 2Maeil Dairy Industry Co., Ltd.

Abstract

PURPOSE
A prospective, controlled trial was conducted to evaluate growth, bone mineralization, and nutritional status receiving preterm human milk supplemented with a newly formulated Maeil human milk fortifier. METHODS: Twenty five fortified human milk-fed and preterm formula-fed infants with a birth weight < 1, 800 g and gestational age <35 weeks, who were born at Ajou University Hospital from March, 2003 through August, 2004 were studied. Growth, biochemical indices of bone mineralization, feeding tolerance, morbidity and wrist X-ray were assessed serially. Total body bone mineral density was measured by dual energy X-ray absorptiometry at 2 and 5months of age. RESULTS: There were no differences in growth, including weight, height and head circumference, between two groups. Serum Ca, P, ALP and other biochemical indices were similar. Although low grade rickets (grade I and II) were occasionally found on wrist X-ray, the rate of occurrence and severity were similar. The bone mineral densities of both group showed no difference. CONCLUSION: The fortified human milk-fed infants and preterm formula-fed infants showed no difference in growth, and bone mineralization. This newly formulated Maeil human milk fortifier can be safely used in preterm infants.

Keyword

Human milk fortifier; Growth; Bone mineralization

MeSH Terms

Absorptiometry, Photon
Birth Weight
Bone Density
Calcification, Physiologic*
Gestational Age
Head
Humans*
Infant
Infant, Newborn
Infant, Premature*
Milk, Human*
Nutritional Status
Prospective Studies
Rickets
Wrist
Full Text Links
  • JKSN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr